Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia

NCT07296445 is registered in ClinicalTrials.gov with SDK Therapeutics, Inc. as lead sponsor.

NCT NCT07296445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07296445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia
Lead sponsor
SDK Therapeutics, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
January 31, 2029
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukaemia, acute promyelocytic leukemia, acute promyelocytic leukemia (apl), acute promyelocytic leukemia with pml-rara, acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); pml-rara, apl, leukaemia, leukemia acute promyelocytic leukemia (apl), leukemia, acute